Delcath Systems, Inc.
DCTH
Rank in Stocks
#10376
Delcath Systems, Inc. is an interventional oncology firm operating in the... Delcath Systems, Inc. is an interventional oncology firm operating in the United States and Europe, dedicated to developing treatments for both primary and secondary liver cancers. Its leading investigational product is the HEPZATO KIT, a unique hepatic delivery system for melphalan that targets high-dose chemotherapy specifically to the liver. This innovative approach aims to substantially reduce systemic drug exposure and mitigate associated side effects. HEPZATO's clinical evaluation is advancing through the FOCUS trial, which is designed to assess the objective response rate in individuals with metastatic uveal melanoma whose disease is primarily concentrated in the liver. Furthermore, the company offers a separate version of HEPZATO as a medical device in Europe, marketed under the CHEMOSAT Hepatic Delivery System brand (or simply CHEMOSAT). This system empowers European medical centers to manage a diverse array of liver cancer conditions. Delcath Systems, Inc. was established in 1988, with its corporate headquarters situated in New York, New York.
Share Price
$20.27
Last synced: 2026-11-09
Market Cap
$703.34M
Change (1 day)
35.77%
Change (1 year)
135.97%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Delcath Systems, Inc. (DCTH)
Category
Healthcare
Operating Margin for Delcath Systems, Inc. (DCTH)
Operating Margin as of November 2026 TTM: -1.90%
According to Delcath Systems, Inc.'s latest financial reports, its current operating margin (TTM) is -1.90%. At the end of 2025 the company had an operating margin of 0.77%.
Operating Margin history for Delcath Systems, Inc. from 2000 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -1.90% | -346.75% |
| 2025 | 0.77% | -102.31% |
| 2024 | -33.36% | -98.20% |
| 2023 | -1,849.01% | 48.51% |
| 2022 | -1,245.05% | 80.43% |
| 2021 | -690.04% | -46.68% |
| 2020 | -1,294.23% | 2.72% |
| 2019 | -1,260.00% | 58.58% |
| 2018 | -794.57% | 18.76% |
| 2017 | -669.06% | -18.93% |
| 2016 | -825.30% | -5.21% |
| 2015 | -870.64% | -51.79% |
| 2014 | -1,805.80% | -56.80% |
| 2013 | -4,179.62% | -73.16% |
| 2012 | -15,569.65% | 0.00% |
| 2011 | 0.00% | 0.00% |
| 2010 | 0.00% | 0.00% |
| 2009 | 0.00% | 0.00% |
| 2008 | 0.00% | 0.00% |
| 2007 | 0.00% | 0.00% |
| 2006 | 0.00% | 0.00% |
| 2005 | 0.00% | 0.00% |
| 2004 | 0.00% | 0.00% |
| 2003 | 0.00% | 0.00% |
| 2002 | 0.00% | 0.00% |
| 2001 | 0.00% | 0.00% |
| 2000 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -108.02% |
US
|
|
| 18.08% | -109.52% |
IE
|
|
| 21.25% | -111.18% |
US
|
|
| 21.05% | -111.08% |
US
|
|
| 28.09% | -114.78% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Delcath Systems, Inc.'s operating margin
What is Delcath Systems, Inc.'s operating margin?
Delcath Systems, Inc.'s operating margin is -1.90%, as of Nov 2026.
What was Delcath Systems, Inc.'s operating margin in 2025?
In 2025, Delcath Systems, Inc.'s operating margin was 0.77%, compared with -33.36% in 2024.
How has Delcath Systems, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Delcath Systems, Inc.'s operating margin was highest in 2025 (0.77%) and lowest in 2023 (-1,849.01%).
How does Delcath Systems, Inc.'s operating margin compare with similar companies?
Delcath Systems, Inc.'s operating margin (-1.90%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.